Time dependent alterations of serum matrix metalloproteinase-1 and metalloproteinase-1 tissue inhibitor after successful reperfusion of acute myocardial infarction

Satoshi Hirohata, Shozo Kusachi, Masahiro Murakami, Takashi Murakami, Issei Sano, Tomoko Watanabe, Issei Komatsubara, Jun Kondo, Takao Tsuji

Abstract

Objective—To test the hypothesis that changes in serum matrix metalloproteinase-1 (MMP-1) and tissue inhibitors of metalloproteinase-1 (TIMP-1) after acute myocardial infarction reflect extracellular matrix remodelling and the infarct healing process.

Patients—13 consecutive patients with their first acute myocardial infarction who underwent successful reperfusion.

Methods—Blood was sampled on the day of admission, and on days 2, 3, 4, 5, 7, 14, and 28. Serum MMP-1 and TIMP-1 were measured by one step sandwich enzyme immunoassay. Left ventricular volume indices were determined by left ventriculography performed four weeks after the infarct.

Results—Serum concentrations of both MMP-1 and TIMP-1 changed over time. The average serum MMP-1 was more than 1 SD below the mean control values during the initial four days, increased thereafter, reaching a peak concentration around day 14, and then returned to the middle control range. Negative correlations with left ventricular end systolic volume index and positive correlations with left ventricular ejection fraction were obtained for serum MMP-1 on day 5, when it began to rise, and for the magnitude of rise in MMP-1 on day 5 compared to admission. Serum TIMP-1 at admission was more than 1 SD below the mean control value, and increased gradually thereafter, reaching a peak on around day 14. Negative correlations with left ventricular end systolic volume index and positive correlations with left ventricular ejection fraction were obtained for serum TIMP-1 on days 5 and 7, and for the magnitude of rise in TIMP-1 on days 5 and 7 compared to admission.

Conclusions—Both MMP-1 and TIMP-1 showed significant time dependent alteration after acute myocardial infarction. Thus MMP-1 and TIMP-1 may provide useful information in evaluating the healing process as it affects left ventricular remodelling after acute myocardial infarction.

(Heart 1997;78:278-284)

Keywords: left ventriculography; ventricular remodelling; matrix metalloproteinase-1; tissue inhibitor of metalloproteinase-1; fibrosis

Left ventricular volume is one of the major prognostic factors after acute myocardial infarction.^{1,2} Ventricular remodelling is thus important with respect to prognosis.^{3,4} The extracellular matrix plays a vital role not only in the maintenance of ventricular shape but also in ventricular function. Collagen is apparently an essential component of the extracellular matrix, and collagenases and their inhibitors play crucial roles in extracellular matrix homeostasis.⁵ Recent biological studies have identified several distinct matrix metalloproteinases (MMP) and tissue inhibitors of metalloproteinases (TIMP) and have delineated their characteristics.^{5,6} The important roles of MMP and TIMP in cardiovascular disease have been reviewed by Dollery *et al.*⁷ MMP-1, a 54 kDa interstitial collagenase, degrades several types of collagen and other extracellular matrix components, including types I and III collagen, the major types of collagen in the collagen matrix.^{5,7} TIMP-1, a 29.5 kDa sialoglycoprotein, forms a complex with MMP-1^{8,9} and acts as a native inhibitor of MMP-1. Inhibitory regulation of MMP-1 activity is mediated in part by TIMP-1. MMP-1 and TIMP-1 thus contribute bidirectionally to the control of collagen matrix maintenance. During extracellular matrix remodelling, degradation and reformation of extracellular matrix occur, and both MMP and TIMP contribute to this process through the balance of their activities. We hypothesised that changes in serum MMP and TIMP concentrations reflect the extracellular matrix remodelling involved in the infarct healing process and that these changes would thus be correlated with left ventricular volume indices. Although there are reports of increased expression of TIMP in chronic liver disease¹⁰ and rheumatoid arthritis,¹¹ there are none on changes in serum MMP and TIMP after acute myocardial infarction. We therefore examined the relations of serum MMP-1 and TIMP-1 to left ventricular volume indices obtained by left ventriculography in patients after myocardial infarction.

Methods

PATIENTS

To determine the sequential changes in serum MMP-1 and TIMP-1 from the infarct onset day, we studied 13 consecutive patients with their first acute myocardial infarct who were admitted within 12 hours of infarct onset and underwent reperfusion by coronary angio-

The First Department of Internal Medicine, Okayama University Medical School, Okayama 700, Japan
S Hirohata
S Kusachi
M Murakami
T Murakami
I Sano
T Watanabe
I Komatsubara
J Kondo
T Tsuji

Correspondence to:
Dr Shozo Kusachi, The First Department of Internal Medicine, Okayama University Medical School, 2-5-1, Shikata-cho, Okayama 700 Japan; email: zqbkytmn@oka.urban.or.jp
Accepted for publication 15 May 1997

plasty. There were seven men and six women, aged 42 to 75 years, mean 63 (SD 11) years. Reperfusion without flow delay was successfully established in all 13 patients. Consequently, this study did not include patients without reperfusion. Patients with associated diabetes mellitus, depressed renal function, liver disease, or malignant disorders were excluded from the study.

The lesion was located at segment 6 according to the American Heart Association classification¹² in six patients, at segment 7 in six, and at segment 2 in one. Patients in whom the responsible lesion was located in the left circumflex coronary artery were excluded from the study because left ventricular indices were evaluated on left ventriculograms obtained in the right anterior oblique view.

The interval from onset to admission ranged from 0.5 to 12 hours (mean 4.7 hours). Electrocardiographic or enzymatic evidence of reocclusion^{13,14} was not observed in any of the patients. The patency of the infarct related artery was confirmed by follow up coronary angiography performed four weeks after the infarct.

Acute myocardial infarction was diagnosed on the basis of typical chest pain, ST segment elevation of more than 0.1 mV in more than two leads in 12-lead electrocardiography, and a rise of both creatine kinase (CK) and its isoenzyme MB to more than twofold the upper limit of the normal range. Emergency coronary angiography was performed, and reperfusion treatment with coronary angioplasty was attempted. None of the patients had cardiogenic shock that disturbed the liver circulation and caused liver damage.

SERUM MMP-1 AND TIMP-1

Blood samples were drawn immediately after admission and on days 2, 3, 4, 5, 7, 14, and 28. Serum MMP-1 and TIMP-1 concentrations were measured by enzyme immunoassay.¹⁵ A one step sandwich enzyme immunoassay kit (Fuji Chemical Industries, Takaoka, Japan) for human MMP-1 using monoclonal antibodies against the MMP-1 purified from human skin fibroblasts was used to assay for MMP-1, as reported.^{15,16} The antibody used does not react with other collagenases. This assay system detects proMMP-1 and active MMP-1 almost equally. When reactivity with proMMP-1 was postulated as 100%, relative immunoreactivities of this assay system with MMP-1 and TIMP-1 complex and with MMP-1 and TIMP-2 complex were 48% and 3%, respectively.^{15,16} α_2 Macroglobulin does not interfere with this assay system.¹⁵ The detection limit of this MMP-1 assay system is 1.0 ng/ml, and linearity is determined from 1 to 64 ng/ml. The intra-assay and interassay coefficients of variation were 2.0–4.3% and < 5%, respectively.

Serum TIMP-1 concentration was also measured by a one step sandwich enzyme immunoassay kit (Fuji Chemical Industries, Takaoka, Japan) using a monoclonal antibody purified from bovine dental pulp TIMP which cross reacts with human TIMP-1.^{16,17} The

immunoassay system for TIMP-1 reacts almost equally with free TIMP-1 and with TIMP-1 complexed with MMP-1, -2, -3, and -9.¹⁶ The detection limit of this TIMP-1 assay system is 1.2 ng/ml, and linearity is determined from 51 to 2000 ng/ml. The intra-assay and interassay coefficients of variation were 1.9–4.5% and 2.8–4.3 %, respectively. The control range for MMP-1 and TIMP-1 was obtained from 18 age and gender matched healthy volunteers aged 62 (SD 7) years (nine men and nine women). The ranges within 1 SD of the mean of the controls for MMP-1 and TIMP-1 and the means (SD) were 3.2–34.5 ng/ml (13.1 (9.3) ng/ml) and 109–177 ng/ml (139 (20) ng/ml), respectively.

LEFT VENTRICULOGRAPHY

Left ventriculography was performed approximately four weeks after the onset of acute myocardial infarction. The left ventriculogram was analysed using a digitiser and a computer (Sony Graphtec Digitiser KD4030B, Tokyo, Japan). The end diastolic frame was determined as the frame nearest the peak of the R wave, using an electrocardiogram recorded simultaneously on cine film. The frame with the smallest ventricular volume was taken to show the end systolic volume, and ventricular volume was calculated by a modification of Dodge's formula.¹⁸ Further, regional ventricular function was determined by centreline method.¹⁹ The regional wall motion of the infarct area was also scored visually follows: 4 = dyskinesis; 3 = akinesis; 2 = severe hypokinesis; 1 = hypokinesis; 0 = almost unaltered or mildly reduced wall motion.

CREATINE KINASE RELEASE

Blood samples for CK assay were obtained immediately upon admission and every four hours thereafter for 48 hours, and then were collected once every day. CK activities were measured by the modified Rosalski method.²⁰ Total CK release was calculated according to a modification of a method reported by Norris *et al.*²¹ and Shell *et al.*²² The duration from the onset to peak CK time was also determined.²³

STATISTICAL ANALYSIS

We employed analysis of variance (ANOVA) to assess time dependent alterations in serum MMP-1 and TIMP-1 concentrations. Pearson's correlation analysis was used to examine the relations between MMP-1/TIMP-1 and left ventricular volume indices, and Spearman's correlation analysis to determine the relation between MMP-1/TIMP-1 and the wall motion score of the infarct region. A P value of < 0.05 was considered statistically significant. Values are given as mean (SD).

Results

MMP-1

Time course

Figure 1 shows the time dependent alteration of the serum MMP-1 concentration after acute myocardial infarction in the 13 patients examined. In five of them, MMP-1 was not

Figure 1 Sequential changes in serum MMP-1 concentrations in patients with acute myocardial infarction. Upper, middle, and lower lines indicate the concentrations at 1 SD above the mean control value, the mean control value, and 1 SD below the mean control value, respectively. Each bar indicates 1 SD.

detectable on the admission day, that is, it was less than 1 ng/ml as measured by the present assay method. For further statistical analysis, undetectable concentrations of MMP-1 were specified as 1 ng/ml. The duration from the onset of acute myocardial infarction to blood sampling was not correlated with the serum MMP-1 concentrations on the admission day. The average serum MMP-1 values measured at each time from the admission day to day 4 were more than 1 SD below the mean control value. MMP-1 began to increase at day 5 and reached its maximum concentration at around day 14. It then decreased and returned to the middle control range at day 28. ANOVA showed that this change was significant ($P < 0.01$).

Relations to left ventricular indices

Serum MMP-1 on day 5, when it began to increase into the normal range, was negatively correlated with the left ventricular end systolic volume index and positively correlated with the left ventricular ejection fraction (fig 2). The magnitude of the rise in MMP-1 on day 5 with respect to the admission value was also inversely correlated with the left ventricular end systolic volume index ($r = -0.56$, $P < 0.05$) and positively correlated with the left ventricular ejection fraction ($r = 0.59$, $P < 0.05$). No significant relation between serum MMP-1 values and left ventricular end diastolic volume index was obtained on any day. Neither the values on the averaged peak day (day 14) nor those on the individual peak days were correlated with any of the indices.

Relation to regional wall motion

The percent area of less than -2 SD/chord in 13 patients ranged from 0% to 48% (22.51(8.3)%). The serum MMP-1 concentration on day 5 was correlated with the percentage area less than -2 SD/chord (fig 2). The magnitude of change in the serum values on day 5 compared to those on admission tended to be related to the area ($r = 0.53$,

Figure 2 Relations of serum MMP-1 concentrations to left ventricular indices obtained four weeks after the onset of acute myocardial infarction. Relation of serum MMP-1 concentrations on day 5 to: (upper panel) left ventricular end systolic volume indices; (middle panel) left ventricular ejection fraction; (lower panel) percentage area less than -2 SD/chord. LVESVI, ventricular end systolic volume index; LVEF, left ventricular ejection fraction. Empty squares, filled triangles, empty triangles, filled circles, and empty circles indicate wall motion scores of 4, 3, 2, 1, and 0, respectively. The lines are the regression line bounded by the 95% confidence intervals.

$0.10 > P > 0.05$). Similarly, the serum concentrations on day 5 and the magnitude of serum concentration changes on day 5 compared to those on admission were both correlated with wall motion score ($r = -0.68$, $P < 0.05$ and $r = -0.73$, $P < 0.01$, respectively).

Relation to CK release

Serum MMP-1 concentrations on day 5 and the magnitude of change of the serum concentrations on day 5 compared to the values on admission were not significantly correlated with CK release or time to CKmax, though the values on day 5 tended to be related to the integral CK release ($r = -0.55$, $0.10 > P > 0.05$).

Figure 3 Sequential changes in serum TIMP-1 concentrations in patients with acute myocardial infarction. Upper, middle, and lower lines indicate the concentrations at 1 SD above the mean control value, the mean control value, and 1 SD below the mean control value, respectively. Each bar indicates 1 SD.

TIMP-1

Time course

The sequential changes in TIMP-1 after acute myocardial infarction in the 13 patients are shown in fig 3. The time from onset of acute myocardial infarction to blood sampling was not correlated with serum TIMP-1 on admission. As with MMP-1, mean serum TIMP-1 at admission was more than 1 SD below the mean control value. It then increased and reached a maximum at around day 14, subsequently decreasing to within the normal range for controls. ANOVA again showed that this change was significant ($P < 0.01$).

Relations to left ventricular indices

As with MMP-1, serum TIMP-1 values on day 5 and day 7 were negatively correlated with left ventricular end systolic volume index ($r = -0.76$, $P < 0.01$, and $r = -0.58$, $P < 0.05$, respectively), and positively correlated with the left ventricular ejection fraction ($r = 0.84$, $P < 0.01$, and $r = 0.79$, $P < 0.05$, respectively) (fig 4). The magnitude of the rise in serum TIMP-1 on day 5 and day 7 was negatively correlated with the left ventricular end systolic volume index ($r = -0.78$, $P < 0.01$, and $r = -0.62$, $P < 0.05$, respectively) and positively correlated with the left ventricular ejection fraction ($r = 0.79$, $P < 0.01$, and $r = 0.63$, $P < 0.05$, respectively). Neither the values on the averaged peak day (day 14) nor those on the individual peak days were correlated with any of the indices.

Relation to regional wall motion

Serum TIMP-1 values on day 5 and day 7 were correlated with percentage area less than -2 SD/chord ($r = -0.84$, $P < 0.01$, and $r = -0.65$, $P < 0.05$, respectively) (fig 4). The magnitude of the change of the serum concentrations on the respective days compared to those on admission were also correlated with

Figure 4 Relations of serum TIMP-1 concentrations to left ventricular indices obtained four weeks after the onset of acute myocardial infarction. Relation of serum TIMP-1 concentrations on day 5 to: (upper panel) left ventricular end systolic volume index; (middle panel) left ventricular ejection fraction; and (lower panel) the percentage area less than -2 SD/chord. LVEF, left ventricular ejection fraction. Empty squares, filled triangles, empty triangles, filled circles, and empty circles indicate wall motion scores of 4, 3, 2, 1, and 0, respectively. The lines are the regression line bounded by the 95% confidence intervals.

the area ($r = -0.83$, $P < 0.01$, and $r = -0.66$, $P < 0.05$, respectively). Similarly, the serum concentrations on day 5 and day 7 were correlated with wall motion score ($r = -0.92$, $P < 0.01$, and $r = -0.66$, $P < 0.05$, respectively). The magnitude of the serum concentration changes on day 5 and day 7 with respect to the admission values was correlated with the wall motion score ($r = -0.91$, $P < 0.01$, and $r = -0.68$, $P < 0.05$, respectively).

Relation to CK release

Neither the serum TIMP-1 on day 5 nor the magnitude of serum concentration changes on day 5 compared to the admission values was significantly correlated with the CK release or with the duration from onset to CKmax.

Discussion

This study showed that the serum concentrations of both MMP-1 and TIMP-1 changed significantly and time dependently from low concentrations, below the control range, to above the control range after acute myocardial infarction. At the time when serum MMP-1 began to rise from its initially low value, serum concentrations of both MMP-1 and TIMP-1 were negatively correlated with the left ventricular end systolic volume index and positively correlated with the left ventricular ejection fraction. There were similar relations between the rise in MMP-1 and TIMP-1 concentrations from their admission values and the left ventricular end systolic volume index and ejection fraction.

The methods we used for determining serum MMP-1 and TIMP-1 are well established,¹⁵⁻¹⁷ and the intra-assay and interassay coefficients of variation are sufficiently small. Left ventriculography was performed in a single projection (the right anterior oblique view). Greene *et al*¹⁸ reported a good correlation between the left ventricular volumes measured using single plane and biplane methods. Moreover, we carefully selected only patients with lesions located in the left anterior descending coronary artery or the right coronary artery territory. These considerations suggest that the methods we used are valid.

The concentrations of MMP-1 on days 1 to 4 and of TIMP-1 on the admission day were more than 1 SD below the mean for the control value. Both MMP-1 and TIMP-1 are tightly controlled by a variety of mechanisms and play important roles in extracellular matrix degradation and remodelling. Although our study did not provide any evidence relating to the mechanism by which the serum concentrations are affected in acute myocardial infarction, the low values might be explained by one or more of three mechanisms: (1) reduced synthesis, (2) increased turnover of serum MMP-1 and TIMP-1, and (3) changes in equilibrium between serum and tissue concentrations, that is, reduced release from tissue or mobilisation from serum to tissue.

REDUCED SYNTHESIS

Regarding synthesis of MMP-1, Cleutjens *et al*²⁴ showed increased MMP-1 activity in infarct tissue by zymography, followed by increments of MMP-1 mRNA, in experimental infarction in rats. Tumour necrosis factor α (TNF α) and interleukin-1 (IL-1) are known to be potent stimulators of MMP-1 at transcriptional level.²⁵ It was also suggested that an increase in circulating cytokines contributes to raised MMP-3 concentrations in patients with rheumatoid arthritis.²⁶ Herskowitz *et al*²⁷ examined proinflammatory cytokines in the infarct by northern blotting after reperfusion following acute myocardial infarction in rats, and showed that TNF α mRNA and IL-1 β mRNA in the infarct tissue both increased, with two peaks—1 to 2 hours after reperfusion and on day 7. Increased serum TNF α concentrations, measured by enzyme linked immunosorbent assay, have also been found in the

early phase of human acute myocardial infarction.²⁸ This reported evidence about the influence of cytokines on MMP suggests that the synthesis of MMP is enhanced rather than depressed. Further, increased concentrations of tissue plasminogen activator, which converts plasminogen to plasmin, have been found in the acute phase by the double antibody sandwich method,²⁹ and plasmin is also known to activate MMP.⁷ Coexpression of MMP and TIMP has been shown in the myocardium³⁰ and human burn wounds,³¹ indicating that extracellular matrix degradation and reformation are regulated through the balance of concomitant expression of MMP and TIMP. These lines of evidence indicate that synthesis or activation of MMP-1 and TIMP-1 is more likely to be enhanced than reduced in the early phase of acute myocardial infarction.

TURNOVER

With respect to serum turnover of MMP-1 and TIMP-1, activated collagenase can be disrupted by α_2 macroglobulin^{32,33} or acute inflammatory reactant, and it is possible that these substances reduced the serum concentrations of MMP-1 and/or TIMP-1. However, in this study no significant correlation was obtained between either serum C reactive protein or neutrophil counts and the serum concentrations of MMP-1 and TIMP-1 on the day of admission or day 5. α_2 Macroglobulin has been shown not to interfere with the measurements of MMP-1 in the present assay system.¹⁵ Furthermore, the serum α_2 macroglobulin concentrations do not differ in patients with acute myocardial infarction and controls.²⁹ Although we found no reported data on the serum half life of MMP-1 and TIMP-1 in acute myocardial infarction and were unable to provide data on this from our study, we do not believe that acute inflammatory reactants and α_2 macroglobulin could account for the low initial serum concentrations of MMP-1 and TIMP-1.

CHANGES IN EQUILIBRIUM BETWEEN SERUM AND TISSUE

Mobilisation of MMP-1 and TIMP-1 from the blood stream to the infarct tissue or their decreased release into to the blood stream from the tissues might explain the initial low levels, though this explanation is entirely speculative. Tyagi *et al*³⁰ showed that MMP are present in the endothelium and subendothelial space of the endocardium and throughout the interstitial spaces of rat hearts. Cleutjens *et al*²⁴ examined MMP-1 and TIMP-1 by zymography, northern blotting, and in situ hybridisation in experimental myocardial infarction in rats and postulated activation of latent MMP-1 pooled in the interstitial spaces as the initial process, and synthesis of collagenase mRNA when pooled MMP is reduced. These findings suggest that the release of MMP into serum would be reduced. They also showed that TIMP mRNA increased six hours after coronary ligation and reached a maximum level on day 2, remaining high by day 7. These experi-

mental results and our observation of initially low serum concentrations of both MMP-1 and TIMP-1 lead us to speculate that activation of pooled latent MMP-1 is the initial process, but that the production of MMP-1 and TIMP-1 does not exceed their local consumption. Mobilisation from the blood stream to the interstitial spaces or reduction in release from myocardial tissue to the serum seem to be the most likely explanations for their low initial serum concentrations.

The concentrations of both MMP-1 and TIMP-1 at the time when MMP-1 began to increase into the control range were correlated with the left ventricular end systolic volume index and ejection fraction, and with the regional wall motion of the infarct, but the average peak day (day 14) concentrations or the individual peak concentrations were not correlated with any of the left ventricular indices. This suggests that the serum values of both MMP-1 and TIMP-1 reflect the healing stages of the infarct rather than the precise activity of infarct fibrogenesis. Thus, prolonged healing of the infarct might be reflected in delayed return of these serum values, resulting in low values at the time when the MMP-1 was beginning to return to the control range, whereas faster healing might be reflected in a faster return, resulting in relatively high normal range values on that day. This could explain the relation of their sequential changes to left ventricular indices, although we emphasise that this is entirely speculative.

It is well known that healing speed is correlated with infarct size. Although we found no significant correlation of serum concentrations of MMP-1 or TIMP-1 on day 5 with integral CK release, and the serum MMP-1 concentrations on day 5 showed a weak non-significant relation to the integral CK release, the values were correlated with percentage area less than -2 SD/chord, which indicates infarct area.¹⁹ Integral CK release indicates loss of myocytes, whereas it is theoretically reasonable to suppose that MMP-1 and TIMP-1 act in response to extracellular matrix damage caused by the infarct. It can also be surmised that the extracellular matrix structure differs from patient to patient with respect to the number of myocytes. This would at least partly account for the lack of a direct correlation between the integral CK release and sequential changes of MMP-1 and TIMP-1.

Extracellular matrix degradation and reformation is regulated through the balance between MMP and TIMP. We cannot comment on this in detail because the immunoassay we used detects not only proMMP-1 and active MMP-1 but also MMP-1 complexed to TIMP-1, and conversely the TIMP-1 assay system detects TIMP-1 together with TIMP-1 complexed with MMPs.

LIMITATIONS OF THE STUDY

This study has several apparent limitations. First, because of careful selection, a relatively small number of patients was included. Second, the assay system used in this study for MMP-1 could not distinguish active MMP-1

from proMMP-1 or from MMP-1 complexed with TIMPs. Similarly, the assay system for TIMP-1 could not distinguish free TIMP-1 from TIMP-1 conjugated with MMPs. The present assay method detected almost all MMP-1 and TIMP-1. Thus this study could not provide further information on various forms of MMP-1 and TIMP-1.

CONCLUSION

Our study demonstrated sequential changes in the serum MMP-1 and TIMP-1 concentrations after acute myocardial infarction, and indicated that the measurement of these enzymes may provide useful information on left ventricular remodelling.

- 1 Kostuk WJ, Kazamias TM, Gander MP, Simon AL, Ross J. Left ventricular size after acute myocardial infarction: serial changes and their prognostic significance. *Circulation* 1973;47:1174-9.
- 2 White HD, Norris RM, Brown MA, Brandt PWT, Whitelock RML, Wild CJ, et al. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. *Circulation* 1987;76:44-51.
- 3 Weisman HF, Healy B. Myocardial infarct expansion, infarct extension, and reinfarction: pathophysiologic concepts. *Prog Cardiovasc Dis* 1987;30:73-110.
- 4 Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. *Circulation* 1990;81:1161-72.
- 5 Matrisian LM. Metalloproteinases and their inhibitors in matrix remodeling. *Trends Genet* 1990;6:121-5.
- 6 Werb Z. The biologic role of metalloproteinases and their inhibitors. In: Kuettner K, Schleyerbach R, Peyron JG, Hascall VC, eds. *Articular cartilage and osteoarthritis*. New York: Raven Press, 1992:295-305.
- 7 Dollery CM, McEwan JR, Henney AM. Matrix metalloproteinases and cardiovascular disease. *Circ Res* 1995;77:863-8.
- 8 Cawston TE, Galloway WA, Mercer E, Murphy G, Reynolds JJ. Purification of rabbit bone inhibitor of collagenase. *Biochem J* 1981;195:159-65.
- 9 Murphy G, Cawston TE, Reynolds JJ. An inhibitor of collagenase from human amniotic fluid. Purification, characterization and action on metalloproteinases. *Biochem J* 1981;195:167-70.
- 10 Murawaki Y, Kawasaki H, Burkhardt H. Serum collagenase activity in chronic liver diseases. *Path Res Pract* 1994;190:929-33.
- 11 Yoshihara Y, Obata K, Fujimoto N, Yamashita K, Hayakawa T, Shimmei M. Increased levels of stromelysin-1 and tissue inhibitor of metalloproteinases-1 in sera from patients with rheumatoid arthritis. *Arthritis Rheum* 1995;38:969-75.
- 12 Austen WG, Edwards JE, Frye RL, Gensini GG, Gott VL, Griffith LSC, et al. A reporting system on patients evaluated for coronary artery disease. Report of the ad hoc committee for grading of coronary artery disease, Council on Cardiovascular Surgery, American Heart Association. *Circulation* 1975;51(suppl):5-40.
- 13 Klootwijk P, Cobbaert C, Fioretti P, Kint PP, Simoons ML. Noninvasive assessment of reperfusion and reocclusion after thrombolysis in acute myocardial infarction. *Am J Cardiol* 1993;72:75-84G.
- 14 Arnold AZ, Topol EJ. Assessment of reperfusion after thrombolytic therapy for myocardial infarction. *Am Heart J* 1992;124:441-7.
- 15 Zhang J, Fujimoto N, Iwata K, Iwata H, Sakai T, Okada Y, et al. A one-step sandwich enzyme immunoassay for human matrix metalloproteinase-1 (interstitial collagenase) using monoclonal antibodies. *Clin Chim Acta* 1993;219:1-14.
- 16 Fujimoto N, Iwata K. Enzyme immunoassay for matrix metalloproteinases and their inhibitors. *Connective Tissue* 1994;26:237-44 (Japanese with English abstract and tables).
- 17 Kodama S, Iwata K, Iwata H, Yamashita K, Hayakawa T. Rapid one-step sandwich enzyme immunoassay for tissue inhibitor of metalloproteinases: an application for rheumatoid arthritis serum and plasma. *J Immunol Methods* 1990;127:103-8.
- 18 Greene DG, Carlisle R, Grant C, Bunnell IL. Estimation of left ventricular volume by one-plane cineangiography. *Circulation* 1967;35:61-9.
- 19 Sheehan FH, Bolson EL, Dodge HT, Mathey DG, Schofer J, Woo HW. Advantages and applications of the centerline method for characterizing regional ventricular function. *Circulation* 1986;74:293-305.
- 20 Rosalki SB. An improved procedure for serum creatine phosphokinase determination. *J Lab Clin Med* 1967;69:696-705.
- 21 Norris RM, Whitlock RM, Barratt-Boyes C, Small CW. Clinical measurement of myocardial infarct size. Modification of a method for the estimation of total crea-

- tine phosphokinase release after myocardial infarction. *Circulation* 1975;51:614-20.
- 22 Shell WE, Kjekshus JK, Sobel BE. Quantitative assessment of the extent of myocardial infarction in the conscious dog by means of analysis of serial changes in serum creatine phosphokinase activity. *J Clin Invest* 1971;50:2614-25.
 - 23 Horie M, Yasue H, Omote S, Takizawa A, Nagao M, Nishida S, et al. A new approach for the enzymatic estimation of infarct size: serum peak creatine kinase and time to peak creatine kinase activity. *Am J Cardiol* 1986;57:76-81.
 - 24 Cleutjens JP, Kandala JC, Guarda E, Guntaka RV, Weber KT. Regulation of collagen degradation in the rat myocardium after infarction. *J Mol Cell Cardiol* 1995;27:1281-92.
 - 25 Lefebvre V, Peeters-Joris C, Vaes G. Modulation by interleukin-1 and tumor necrosis factor of production of collagenase, tissue inhibitor of metalloproteinases and collagen types in differentiated and dedifferentiated articular chondrocytes. *Biochim Biophys Acta* 1990;1052:366-78.
 - 26 Manicourt D-H, Fujimoto N, Obata K, Thonar EJ. Levels of circulating collagenase, stromelysin-1 and tissue inhibitor of matrix metalloproteinases 1 in patients with rheumatoid arthritis. Relationship to serum levels of antigenic keratan sulfate and systemic parameters of inflammation. *Arthritis Rheum* 1995;38:1031-9.
 - 27 Herskowitz A, Choi S, Ansari AA, Wesselingh S. Cytokine mRNA expression in postischemic/reperfused myocardium. *Am J Pathol* 1995;146:419-28.
 - 28 Latini R, Bianchi M, Correale E, Dinarello CA, Fantuzzi G, Fresco C, et al. Cytokines in acute myocardial infarction: selective increase in circulating tumor necrosis factor, its soluble receptor, and interleukin-1 receptor antagonist. *J Cardiovasc Pharmacol* 1994;23:1-6.
 - 29 Vaziri ND, Kennedy SC, Kennedy D, Gonzales E. Coagulation, fibrinolytic, and inhibitory proteins in acute myocardial infarction and angina pectoris. *Am J Med* 1992;93:651-7.
 - 30 Tyagi SC, Kumar SG, Banks J, Fortson W. Co-expression of tissue inhibitor and matrix metalloproteinase in myocardium. *J Mol Cell Cardiol* 1995;27:2177-89.
 - 31 Stricklin GP, Li L, Jancic V, Wenczak BA, Nanney LB. Localization of mRNAs representing collagenase and TIMP in sections of healing human burn wounds. *Am J Pathol* 1993;143:1657-66.
 - 32 Barrett AJ, Starkey PM. The interaction of α 2-macroglobulin with proteinases. Characteristics and specificity of the reaction, and a hypothesis concerning its molecular mechanism. *Biochem J* 1973;113:709-24.
 - 33 Enghild JJ, Salvesen G, Brew K, Nagase H. Interaction of human rheumatoid synovial collagenase (matrix metalloproteinase 1) and stromelysin (matrix metalloproteinase 3) with human α 2-macroglobulin and chicken ovomucoid. *J Biol Chem* 1989;264:8779-85.